|
November 3 , 2005
MEDICURE TO PRESENT AT BIOTECH INVESTOR CONFERENCE
WINNIPEG, Manitoba Ð (November 3, 2005)
WINNIPEG , Manitoba – (November 3, 2005) Medicure Inc. (TSX:MPH; Amex: MCU), a cardiovascular drug discovery and development company
is pleased to announce it will be presenting at the upcoming Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York City. On Tuesday, November 8, 2005, at 11:55 am Eastern, Albert D. Friesen, PhD, Medicure’s President and CEO, will deliver a corporate presentation in the Holmes II room of the New York Palace Hotel. The presentation will be webcast live and archived on the Medicure website at www.medicure.com.
Listen to webcast
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes:
- Cardiovascular focused pipeline: a global market of over US $70 billion
- Two drugs - MC-1 & MC-4232 - in advanced clinical development
- Three positive Phase II trials completed
- FDA Fast Track designation for MC-1
- Unique products addressing major, inadequately served markets
- Dual action antithrombotic, MC-45308, with positive preclinical results
Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule, anti-ischemics, and antithrombotics towards human clinical studies.
This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such risks, include among others, those described in the Company’s annual return on Form 20-F. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Hogan Mullally
Manager of Investor & Public Relations
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to News Releases
|
|
